The study, published in JAMA Internal Medicine, examined 122 U.S.-based clinical trials, involving more than 175,000 participants, for COVID-19 vaccines or treatments. Trials were published between October 2019 and February 2022.
Here are four key findings:
- Sex, race and ethnicity were reported in 89.3 percent, 77.9 percent and 71.3 percent of U.S.-based COVID-19 clinical trials, respectively, showing a gap in reporting important trial aspects.
- Female participants were underrepresented in treatment trials, at 85 percent of expected participants, but were well represented in COVID-19 prevention trials.
- Black and Asian participants were underrepresented in COVID-19 prevention trials, at 53.7 percent and 64.4 percent of expected participants, respectively, but were well represented in COVID-19 treatment trials.
- Hispanic participants were overrepresented in treatment trials, at more than 200 percent of expected participants.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
